News and Trends 9 Sep 2022
Improved vision with less eye injections for patients after primary endpoints met in trials
The primary endpoints in two clinical trials investigating drug aflibercept 8 mg with 12 and 16-week dosing regimes, for patients with diabetic macular edema (DME) and wet age-related macular degeneration (wAMD), have been met. The trials, called PHOTON in DME and PULSAR in wAMD, both showed the dosing regimens achieved non-inferiority in vision gains compared […]